≥1 vertebral fracture with raloxifene v placebo in postmenopausal osteoporosis at 3 years†
| Women | Raloxifene dose | Raloxifene | Placebo | RRR (95%) | NNT |
|---|---|---|---|---|---|
| †Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | |||||
| All | 60 mg/d | 6.6% | 10.1% | 35% (21 to 47) | 29 (20 to 52) |
| 120 mg/d | 5.4% | 10.1% | 46% (33 to 56) | 22 (17 to 33) | |
| With previous fractures | 60 mg/d | 14.7% | 21.2% | 35% (19 to 48) | 16 (10 to 38) |
| 120 mg/d | 10.7% | 21.2% | 53% (40 to 63) | 10 (7 to 15) | |
| With no previous fractures | 60 mg/d | 2.3% | 4.5% | 47% (22 to 65) | 47 (29 to 120) |
| 120 mg/d | 2.8% | 4.5% | 38% (9 to 57) | 59 (33 to 274) | |